112 related articles for article (PubMed ID: 32868036)
1. Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study.
Nasu I; Shimano R; Kawazoe H; Nakamura T; Miura Y; Takano T; Hayashi M
Clin Ther; 2020 Oct; 42(10):1975-1982. PubMed ID: 32868036
[TBL] [Abstract][Full Text] [Related]
2. Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study.
Kawazoe H; Murakami A; Yamashita M; Nishiyama K; Kobayashi-Taguchi K; Komatsu S; Aoki R; Kusakabe E; Yamasawa H; Yakushijin Y; Nakamura T; Kamei Y
Clin Ther; 2018 Dec; 40(12):2170-2179. PubMed ID: 30392814
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
4. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
Hayashi T; Shimokawa M; Matsuo K; Iihara H; Kawada K; Nakano T; Egawa T
BMC Cancer; 2021 Jan; 21(1):74. PubMed ID: 33451299
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Single-dose First-generation 5-HT
Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
8. Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Waqar SN; Mann J; Baggstrom MQ; Waqar MA; Chitneni P; Williams K; Gao F; Morgensztern D; Govindan R
Acta Oncol; 2016 Jun; 55(6):700-4. PubMed ID: 27145068
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Furukawa N; Akasaka J; Shigemitsu A; Sasaki Y; Nagai A; Kawaguchi R; Kobayashi H
Arch Gynecol Obstet; 2014 Apr; 289(4):859-64. PubMed ID: 24185939
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
[TBL] [Abstract][Full Text] [Related]
11. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract][Full Text] [Related]
13. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
15. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
[TBL] [Abstract][Full Text] [Related]
17. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Iihara H; Shimokawa M; Hayasaki Y; Fujita Y; Abe M; Takenaka M; Yamamoto S; Arai T; Sakurai M; Mori M; Nakamura K; Kado N; Murase S; Shimaoka R; Suzuki A; Morishige KI
Gynecol Oncol; 2020 Mar; 156(3):629-635. PubMed ID: 31926638
[TBL] [Abstract][Full Text] [Related]
19. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
20. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
